Company intelligence / Profile preview

PROVIREX Genome Editing Therapies GmbH

Hamburg, Hamburg, Germanyprovirex.de ↗

Ownership: Private
Development stage: Preclinical

Overview

The company’s lead program uses the proprietary Brec1 designer recombinase to excise integrated HIV DNA from infected cells with nucleotide precision. This approach has advanced to a first-in-human Phase Ib/IIa clinical gene therapy trial at University Medical Center Hamburg, targeting hematopoietic stem cells in people living with HIV. The technology aims to provide a functional cure by permanently removing the virus from patient genomes. Further pivotal trials are planned.

Therapeutic areas: Infectious Diseases
Modalities: Gene editing (designer recombinases, specifically Brec1)
Industry: Biotech

Drug pipeline

1 asset

Brec1

Unknown

Partnerships

University Medical Center Hamburg-Eppendorf/UKE (clinical site)Ascenion GmbH and Innovationsstarter Fonds Hamburg as investors and tech transfer partnersBioventure as investor/funding partner.

Beyond the preview

Go deeper on PROVIREX Genome Editing Therapies GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PROVIREX Genome Editing Therapies GmbH.

Explore the full profile